BiomeSense
BiomeSense develops an AI-enabled technology platform for microbiome data generation and analysis. Its GutLab technology enables continuous tracking of gut microbiome throughout treatment journeys, while the MetaBiome AI Platform transforms data using time-series analyses to identify clinically-relevant shifts and patterns. Founded in 2018 in Chicago, United States, the company has raised $8.4M in seed funding from…
Funding snapshot
About
BiomeSense develops an AI-enabled technology platform for microbiome data generation and analysis. Its GutLab technology enables continuous tracking of gut microbiome throughout treatment journeys, while the MetaBiome AI Platform transforms data using time-series analyses to identify clinically-relevant shifts and patterns. Founded in 2018 in Chicago, United States, the company has raised $8.4M in seed funding from investors including Bluestein Ventures, SOSV, and IndieBio. Developer of AI-enabled technology platform for microbiome data generation and analysis. The company provides continuous, comprehensive microbiome data and AI-enabled bioinformatics. It offers GutLab technology for continuous tracking of the patient's gut microbiome throughout the treatment journey. The company's MetaBiome AI Platform transforms and analyzes the data using time-series analyses, enabling identification of clinically-relevant shifts and patterns.
Business model
Life Sciences Tech > Research & Development > Scientific Sourcing > Research Groups > Microbiome Research,
Genomics > Applied Genomics > Consumer Genomics > Microbiomics,
SOSV Batches > INDIE.BIO > Cohort 08
Founders & team highlights
Serial Founder
Team background
College Wise > Stanford University, King’s College London, Booth School of Business, University of Chicago
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.